PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Liver Cirrhosis, Biliary

Drugs in development · updated 30 October 2026

Liver Cirrhosis, Biliary: drugs in development

Rare diseasePrevalence 1-5 / 10 000 according to Orphanet · ORPHA:186

As of 30 October 2026 there are 28 active clinical trials (recruiting or ongoing, phases I–III) on 13 drugs for liver Cirrhosis, Biliary. 4 are experimental, that is not yet approved in the United States.

28Active trials
4Experimental drugs
2Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
Saroglitazar MagnesiumIII4NCT07424677
CS0159III2NCT07282353
CilofexorII1NCT07841977
VolixibatII1NCT05050136

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
FenofibrateFenoglide®, Antara (Micronized)®II–III9NCT06365424
UDCAUrsodeoxycholic Acid, UrsodiolII–III8NCT06365424
ElafibranorIqirvo®III3NCT06730061
SeladelparIII3NCT06051617
LinerixibatLynavoy®III2NCT07860710
PrednisonePredinisone, CortancylII–III1NCT06591468
NalmefeneZurnai (Autoinjector)®, Opvee®II1NCT06733519
NemolizumabNemluvio®II1NCT07843420
UpadacitinibRinvoq Lq®, Rinvoq®II1NCT07678645

Sorted by most advanced phase and number of active trials.

All 13 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D008105 “Liver Cirrhosis, Biliary”. Prevalence: Orphanet.

ItalianoFrançaisDeutsch